Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson’s Disease

Publisher： Bentham Science Publishers

E-ISSN： 1996-3181|13|1|120-125

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.13, Iss.1, 2014-02, pp. : 120-125

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vasoactive intestinal peptide family as a therapeutic target for Parkinson’s disease

By Gonzalez-Rey Elena   Chorny Alejo   Fernandez-Martin Amelia   Varela Nieves   Delgado Mario  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 5, 2005-10 ,pp. : 923-929

Informa Healthcare

Access to resources Recommend Favorite

Emerging Therapies in the Pharmacological Treatment of Parkinson’s Disease

By Korczyn A.D.   Nussbaum M.  

Drugs, Vol. 62, Iss. 5, 2002-01 ,pp. : 775-786

Adis International

Access to resources Recommend Favorite

Recent developments in the pharmacological treatment of Parkinson’s disease

By Tuite Paul   Riss Jennifer  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 8, 2003-08 ,pp. : 1335-1352

Informa Healthcare

Access to resources Recommend Favorite

C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 17, Iss. 1, 2018-04 ,pp. : 14-21

Bentham Science Publishers

Access to resources Recommend Favorite

Novel pharmacological strategies for motor complications in Parkinson’s disease

By Konitsiotis Spiros  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 4, 2005-04 ,pp. : 377-392

Informa Healthcare

Access to resources Recommend Favorite